Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Otwarte badanie mające na celu zbadanie ECUR-506 u dzieci płci męskiej w wieku poniżej 9 miesięcy z noworodkowym niedoborem OTC (OTC-HOPE)

29 września 2026 zaktualizowane przez: iECURE, Inc.

Pierwsze przeprowadzone na ludziach, otwarte badanie fazy I/II dotyczące zwiększania dawki, mające na celu ocenę bezpieczeństwa i skuteczności pojedynczego dożylnego (IV) podania ECUR-506 u mężczyzn w wieku poniżej 9 miesięcy z genetycznie potwierdzonym początkiem noworodkowym Niedobór transkarbamylazy ornitynowej (OTC).

Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for detoxifying of ammonia. Individuals with OTC deficiency can develop elevated levels of ammonia in the blood, potentially resulting in severe consequences, including cumulative and irreversible neurological damage, coma, and death. The most severe form presents shortly after birth and occurs more commonly in boys than girls.

This is a Phase 1/2/3, open-label, multicenter study evaluating the safety, efficacy, and dose of ECUR-506 in male babies with neonatal-onset OTC deficiency. The primary objective is to evaluate the safety, tolerability, and efficacy of up to three dose levels of ECUR-506 following intravenous (IV) administration of a single dose.

Przegląd badań

Status

Aktywny, nie rekrutujący

Warunki

Interwencja / Leczenie

Szczegółowy opis

The study drug, ECUR-506, is an investigational gene editing therapy. Gene editing is an approach used to repair, replace, or introduce functional copies of genes that are not working properly. ECUR-506 contains a functional copy of the OTC gene, along with a gene to encode an editing enzyme that enables insertion of the OTC gene into the genome. The study drug is administered as a single IV infusion. Because genes cannot enter cells on their own, ECUR-506 uses a delivery system based on adeno-associated virus (AAV), a commonly used viral vector, to transport the genetic material into cells.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

20

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • New South Wales
      • Sydney, New South Wales, Australia
        • The Children's Hospital at Westmead
    • Victoria
      • Melbourne, Victoria, Australia, 3052
        • The Royal Children's Hospital
      • Barcelona, Hiszpania, 08950
        • Hopsital Sant Joan de Deu
      • Madrid, Hiszpania, 28041
        • Hospital Universitario 12 de Octubre
    • California
      • Los Angeles, California, Stany Zjednoczone, 90095
        • UCLA Mattel Children's Hospital
    • Colorado
      • Aurora, Colorado, Stany Zjednoczone, 80045
        • Children's Hospital of Colorado, Anshutz Medical Campus
    • Georgia
      • Atlanta, Georgia, Stany Zjednoczone, 30322
        • Emory University School of Medicine
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60611
        • Ann & Robert H. Lurie Children's Hospital of Chicago
    • New York
      • New York, New York, Stany Zjednoczone, 10029
        • Icahn School of Medicine at Mount Sinai
    • Oregon
      • Portland, Oregon, Stany Zjednoczone, 97239
        • Oregon Health and Science University
      • London, Zjednoczone Królestwo
        • Great Ormond Street Hospital
      • Newcastle upon Tyne, Zjednoczone Królestwo
        • The Newcastle upon Tyne Hospitals NHS Foundation Trust- Great North Children's Hospital

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

1 dzień do 7 miesięcy (Dziecko)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Męski

Opis

Key Inclusion Criteria:

  1. Male sex
  2. Gestational or adjusted (corrected) gestational age ≥ 37 weeks
  3. Age at screening is 24 hours to 7 months
  4. Weight ≥ 3.5 kg and ≤ 13.5 kg at screening
  5. Has received age-appropriate vaccinations
  6. Genetically confirmed OTCD defined by genetic confirmation of an OTC variant (pathogenic or likely pathogenic) associated with severe neonatal OTCD defined below in Inclusion Criteria #7 or has the same OTC variant as a family member who had severe neonatal OTCD within first week of life.
  7. Severe neonatal OTCD defined by hyperammonemic crisis with elevated ammonia level of >560 μmol/L and clinical symptoms within first week of life, and currently receiving treatment with both dietary protein restriction and nitrogen scavenger therapy.
  8. Current or historical biochemical profile consistent with OTCD
  9. Participant's parent(s)/LAR must be able to comprehend and be willing to provide a signed IRB/IEC-approved ICF.

Key Exclusion Criteria:

  1. Neonatal diagnosis of severe to profound Hypoxic Ischemic Encephalopathy due to birth injury
  2. Requiring urgent liver transplant due to liver failure as assessed by the PI.
  3. Contiguous gene deletion involving the OTC gene and including at least the CYBB gene on the telomeric side or the TSPAN7 gene on the centromeric side.
  4. Known or suspected major organ injury/dysfunction/anomalies.
  5. Vital sign and laboratory abnormalities outside of reference ranges.
  6. Treatment with any other gene therapy or gene editing therapy
  7. Co-enrollment in any other study unless approved by the sponsor.
  8. Any condition, that in the opinion of the Investigator, would compromise the safety of the participant or study data
  9. Documented vertical transmission of HepA/HepB/HepC
  10. Documented in-utero teratogen, substance, and/or alcohol exposure, which in the opinion of the Investigator may increase the participant's risk of developmental delays, congenital anomalies, and/or significant medical complications

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nielosowe
  • Model interwencyjny: Zadanie sekwencyjne
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Low Dose Level

Participants will receive the Low Dose of ECUR-506 delivered one time via IV Infusion.

ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene.

Eksperymentalny: Intermediate Dose Level

Participants will receive an intermediate dose of ECUR-506 delivered on time via IV infusion

ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene.

Eksperymentalny: High Dose Level

Participants will receive a higher dose of ECUR-506 delivered one time via IV infusion.

ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Treatment-emergent adverse events (incidence, severity, seriousness, and relatedness)
Ramy czasowe: Over 24 weeks post infusion

Toxicity is graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Adverse events (AEs) are reported based on clinical laboratory tests, vital signs, physical examinations, Pediatric Neurologist exam parameters, electrocardiograms, and any other medically indicated assessments from the time informed consent is signed through the end of the safety follow-up period.

AEs are considered to be treatment emergent (TEAE) if they occur or worsen in severity following the administration of the study treatment. TEAEs are considered treatment-related if relationship to study drug is possibly related, probably related, or definitely related.

Over 24 weeks post infusion
Physical exam parameters
Ramy czasowe: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.

Safety- (Includes PI assessment of General Appearance, Dermatological, HEENT, Lymphatic, Respiratory, Cardiovascular, Gastrointestinal, Musculoskeletal, Neurological (Cranial Nerve Function, Motor System Function, Sensory System Function, Primitive Reflexes))

Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
Vital sign parameters
Ramy czasowe: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.

Safety- (Includes PI assessment of Systolic Blood Pressure, Diastolic Blood Pressure, Pulse Rate, Respiratory Rate, Temperature)

Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
Pediatric neurologist exam parameters
Ramy czasowe: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.

Safety- (Includes Pediatric Neurologist assessment of Neurological status by review of Cranial Nerve Function, Motor System Function, Sensory System Function, Primitive Reflexes.)

Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
Blood safety tests including hematology, serum chemistry, liver function tests, coagulation tests
Ramy czasowe: as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.

Safety- (Blood Safety tests to be reviewed in relation to established normal ranges for each assessment for the applicable age group)

as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
Urinalysis evaluations
Ramy czasowe: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Toxicity is graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Adverse events (AEs) are reported based on clinical laboratory tests, vital signs, physical examinations, electrocardiograms, and any other medically indicated assessments from the time informed consent is signed through the end of the safety follow-up period.

AEs are considered to be treatment emergent (TEAE) if they occur or worsen in severity following the administration of the study treatment. TEAEs are considered treatment-related if relationship to study drug is possibly related, probably related, or definitely related.

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
12 lead ECG parameters
Ramy czasowe: as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.

Safety- (Includes PI review of Heart Rate, PR Interval, RR Interval, QRS Duration, QT Interval, QTcF Interval, Overall Interpretation)

as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
Complete clinical response
Ramy czasowe: Over 24 weeks post infusion

Discontinuation of scavenger medication for a minimum duration of 28 days without reductions in prescribed daily protein intake during this time period by end of study.

Over 24 weeks post infusion

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Number of HAEs/person-year
Ramy czasowe: Day 1 post dose through Week 24

Key Secondary Endpoint: Pharmacodynamics and Efficacy

Day 1 post dose through Week 24
qPCR measurement to evaluate the clearance of both vectors in body fluids over time
Ramy czasowe: Over 24 weeks post infusion

Supportive Secondary Endpoint: Pharmacokinetics

Over 24 weeks post infusion
Incidence of hyperammonemic episode (HAE)
Ramy czasowe: Over 24 weeks post infusion

Supportive Secondary Endpoint: Pharmacodynamics and Efficacy

Over 24 weeks post infusion
Incidence and number of hyperammonemic episodes (HAE/HAC) resulting in hospitalization
Ramy czasowe: Over 24 weeks post infusion

Supportive Secondary Endpoint: Pharmacodynamics and Efficacy

Over 24 weeks post infusion
Overall and by hospitalization severity (Mild: adjustment of dietary protein intake and oral scavenger medication / Moderate: cessation of dietary protein intake and initiation of IV scavenger therapy / Severe: requirement for hemodialysis)
Ramy czasowe: Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants

Supportive Secondary Endpoint: Pharmacodynamics and Efficacy.

Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants
Duration of hospitalization for each HAE/HAC
Ramy czasowe: Over 24 weeks post infusion

Supportive Secondary Endpoint: Pharmacodynamics and Efficacy

Over 24 weeks post infusion
Requirement for Intensive Care Unit (ICU) care during hospitalization for each HAE/HAC
Ramy czasowe: Over 24 weeks post infusion

Supportive Secondary Endpoint: Pharmacodynamics and Efficacy

Over 24 weeks post infusion
Time to liver transplant from dosing to end of study (EOS)
Ramy czasowe: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Supportive Secondary Endpoint: Efficacy

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Transplant free survival
Ramy czasowe: Time to lever transplant or any-cause death from dosing to EOS

Supportive Secondary Endpoint: Efficacy

Time to lever transplant or any-cause death from dosing to EOS
Overall survival
Ramy czasowe: Time to any-cause death from dosing to EOS

Supportive Secondary Endpoint: Efficacy

Time to any-cause death from dosing to EOS
Achieving and maintaining complete clinical response through end of study
Ramy czasowe: Over 24 weeks post infusion

Supportive Secondary Endpoint: Efficacy

Over 24 weeks post infusion
Scavenger drug dose
Ramy czasowe: Over 24 weeks post infusion

Supportive Secondary Endpoint: Efficacy

Over 24 weeks post infusion
Dietary protein intake g/kg/day
Ramy czasowe: Supportive Secondary: Over 24 weeks post infusion

Supportive Secondary Endpoint: Efficacy

Supportive Secondary: Over 24 weeks post infusion
Blood urea nitrogen measurements
Ramy czasowe: Over 24 weeks post infusion

Supportive Secondary Endpoint: Pharmacodynamics

Over 24 weeks post infusion

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Clinical Response (CR) defined as reduction in baseline standard of care therapy
Ramy czasowe: Assessed at Week 24

Efficacy

Assessed at Week 24
Serum Neurofilament Light Chain
Ramy czasowe: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Safety

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Number of participants with antibodies to AAVrh79 capsid in blood
Ramy czasowe: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Pharmacodynamics

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Number of participants with antibodies to hOTC transgene in blood
Ramy czasowe: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Pharmacodynamics

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Number of participants with antibodies to M2PCSK9 transgene in blood
Ramy czasowe: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Pharmacodynamics

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Incidence and time to medical management adjustments based on iECURE guidance (protein diet or scavenger medication)
Ramy czasowe: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Efficacy

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Fasting plasma ammonia
Ramy czasowe: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Pharmacodynamics

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Fasting plasma citrulline and fasting plasma glutamine levels
Ramy czasowe: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Pharmacodynamics

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Serum PCSK9
Ramy czasowe: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Pharmacodynamics

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Urinary excretion of phenylacetate metabolites
Ramy czasowe: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Urinary phenylacetate (mcg/mL), urinary phenylacetylglutamine (mcg/mL), urinary phenylacetate/ phenylglutamine ratio.

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Urinary excretion of orotic acid metabolites.
Ramy czasowe: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Urinary orotic acid (mmol/ mol creatinine), urinary uracil (mmol/mol creatinine).

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Urinary nitrogen to urinary creatinine ratio.
Ramy czasowe: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Urinary nitrogen to urinary creatinine ratio (mg/dL)

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Change from baseline at Week 24 post infusion in length.
Ramy czasowe: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Length measured in centimeters.

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Change from baseline at Week 24 post infusion in weight.
Ramy czasowe: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Weight measured in kilograms.

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Percent liver transduction via ISH/IF (in-situ hybridization / Immunofluorescence)"at Wk 24 collected by liver biopsy.
Ramy czasowe: The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.

Pharmacodynamics

The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
Assess the potential on and "off" target editing by amplicon-seq in liver tissue samples of participants who received ECUR-506.
Ramy czasowe: The following will be assessed at week 24 if liver biopsy tissue sample is sufficient.

Pharmacodynamics

The following will be assessed at week 24 if liver biopsy tissue sample is sufficient.
Assess potential off-target editing with AAV vector ITR insertion by ITR-seq in liver tissue samples of participants who received ECUR-506
Ramy czasowe: The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.

Pharmacodynamics

The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
Assess for potential genetic changes in the liver tissue, collected by liver biopsy, through long read sequencing, in participants who have received ECUR-506
Ramy czasowe: The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.

Pharmacodynamics

The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
With an observed genetic safety signal, genetic analysis of Whole Blood DNA may be performed on samples collected and stored at screening and week 24, in the event of an observed genomic safety signal.
Ramy czasowe: Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.

Safety

Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.
Change from baseline at Week 24 post infusion in Bayley Scales of Infant and Toddler Development 4th Ed (BSID-4) for the Cognitive, Language, and Motor scales
Ramy czasowe: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Total Raw Scores, Growth Score Values (GSVs), and Age Equivalent Scores will be analyzed; Raw Scores range 0-162; GSVs range 428-599; Age Equivalent Scores range 1-42 months; a higher score reflects a higher level of skill.

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Quality of Life, as measured by the Pediatric QOL inventory Infant Scale (PedsQL-IS)
Ramy czasowe: Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.

Quality of Life

Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Dyrektor Studium: George Diaz, M.D., Ph.D, iECURE, Inc.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

8 kwietnia 2024

Zakończenie podstawowe (Szacowany)

1 grudnia 2027

Ukończenie studiów (Szacowany)

1 grudnia 2027

Daty rejestracji na studia

Pierwszy przesłany

19 grudnia 2023

Pierwszy przesłany, który spełnia kryteria kontroli jakości

2 lutego 2024

Pierwszy wysłany (Rzeczywisty)

13 lutego 2024

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

30 września 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

29 września 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • ECUR-506-OTC-101
  • OTC-HOPE (Inny identyfikator: iECURE, Inc.)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .